More Details9 Jun 2023 10:11
Just posted on LinkedIn
Earlier this week, we announced an extension in our cultivation strategy as we look to pioneer ‘Cannabis 2.0’. Here are the key details ⬇️
🌍 The Medical cannabis market in Europe is rapidly evolving.
🌱 In the last 18 months, cultivators have been struggling with soaring energy costs that have put many out of business, whilst distributors have been building their own EU-GMP facilities, putting into question the need for Hellenic to develop a GMP facility of their own when our customers are already doing so.
💡 In response to this, Hellenic has identified an opportunity that they are uniquely placed to pounce on.
🔬 For the first time, we are offering distributors the opportunity to have their own dedicated cultivation facility by way of a Hellenic POD (“Product Outsourcing Development”).
🏢 Each POD is a fully indoor cultivation area of 1,000 square meters and is capable of producing circa 1,200 kg of medical cannabis flowers per annum.
🤝 Under the Hellenic POD strategy distributors can now fully define or supply the specific strains of medical cannabis they are looking to receive, which Hellenic cultivates and sends out directly to the distributor, branded under the distributors chosen brand name. Each POD can be taken for a minimum of two years.
💰 For distributors, only our facility offers such a low cost of production with such strong expertise, and for us, this new model removes the significant cost of building our own GMP facility, whilst allowing us to focus on leveraging one of our strongest assets, our site in Greece.
🏆 This simplifies our business model, saves us time and expense while maintaining our commitment to excellence and compliance.
🚀 Hellenic is well placed to become the engine room for the European Medical Cannabis market, and we have more exciting announcements on this latest extension soon.
Sign In
Follow the stocks
